Clinical Trial Update: Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports safety and preliminary efficacy data for MAGE-A4 TCR-engineered T cells in patients with malignant solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• MAGE-A4 TCR gene-modified T cells (MAGE-A4 TCR-engineered T cells)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Malignant Solid Tumors | Phase 1 | Status: UNKNOWN